Welcome to ALTG

Feasibility is open for the ILLUMINATE Study (ALTG 16/009) which is a phase 2 trial of durvalumab and tremelimumab with chemotherapy in metastatic EGFR mutant non-squamous non-small cell lung cancer (NSCLC) following progression on epidermal growth factor receptor (EGFR) mutation Tyrosine Kinase Inhibitors (TKIs).

ALTG Speaking Tour:
The purpose of this educational evening is to provide practical evidence-based strategies for use within the multidisciplinary team environment but also to identify potential gaps in research.

For Patients

Upcoming Events